Visit Jessup   Request Info   Apply  

Jessup University

Top Christian College in Northern California

John Brekken

John Brekken

  • Lab Manager

  • School of Natural and Applied Sciences

  • Rocklin, CA

Email John

Biography:

John comes to Jessup with a background in biotechnology where he has extensive experience in cancer research and preclinical studies.  His pharmacology and oncology work with MMPI’s, VEGF inhibitors, and Hsp90 inhibitors has contributed to five Investigational New Drug filings.  One of those filings has resulted in a drug currently being prescribed for cancer treatment.  

John has a passion for team building, efficiency, and all things biology.  He is excited to use his expertise to facilitate and encourage the new generation of God-fearing scientists and health professionals.

Education:

  • Bachelor of Science, Biochemistry - California Polytechnic State University, San Luis Obispo

Publications/Work:

  • Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ.  BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.  Mol Cancer Ther. 2009 8:921-929.

  • Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.  Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.  J Med Chem. 2007 50:2767-78.

  • Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. Identification of new biomarkers for clinical trials of Hsp90 inhibitors.  Mol Cancer Ther. 2006 5:1256-64.

  • Shalinsky, D.R., Brekken, J., Zou, H., Kolis, S., Wood, A., Webber, S. and Appelt, K.  Antitumor efficacy of AG3340 associated with minimum effective plasma concentrations and not total daily dose, exposure, or peak plasma concentrations.  Investigational New Drugs 16: 303-313, 1999

  • Shalinsky, D.R., Brekken, J., Zou, H., Bloom, L., McDermott, C., Varki, N.M.  and Appelt, K.  Marked antiangiogenic and antitumor efficacy of AG3340 in chemo resistant human NSCLC tumors : Single agent and combination chemotherapy studies.    Clinical Cancer Research 5. 1905-1917, July 1999

  • Shalinsky, D.R., Brekken, J., Zou, H., McDermott, C.D., Forsyth, P., Edwards, D., Margosiak, S., Bender, S., Truitt, G., Wood, A., Varki, N.M., and Appelt, K.  Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.  Annals of the New York Academy of Sciences, Vol. 878:236-70, 1999